--- title: "Mosaic ImmunoEngineering (CPMV) stock and investor profile" url: "https://aibio.space/companies/mosaic-immunoengineering/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Mosaic ImmunoEngineering Inc. (OTC: CPMV), United States. The directory classifies it as Biotechnology." --- CPMV Mosaic ImmunoEngineering Inc. OTC · United States # Mosaic ImmunoEngineering (CPMV) news Distress · 2025-08-12 ## [Mosaic ImmunoEngineering delays its June 30, 2025 quarterly report](https://aibio.space/news/mosaic-immunoengineering-delays-june-30-2025-quarterly-report/) Mosaic ImmunoEngineering missed the 5:30 p.m. EDT August 14, 2025 deadline for its second-quarter report, citing financial reporting and close procedures. Its annual report warned it might have to cease operations if a deal with Oncotelic and note-holder waivers were not secured by June 30, 2025. ## Latest Mosaic ImmunoEngineering news We have not published a story on Mosaic ImmunoEngineering yet. When there is news, it will appear here. ## Mosaic ImmunoEngineering at a glance - **Ticker**: CPMV - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $26 ### Related companies - [Editas Medicine](https://aibio.space/companies/editas-medicine/) NASDAQ: EDIT - [Galectin Therapeutics](https://aibio.space/companies/galectin-therapeutics/) NASDAQ: GALT - [SAB Biotherapeutics](https://aibio.space/companies/sab-biotherapeutics/) NASDAQ: SABS - [Amgen](https://aibio.space/companies/amgen/) NASDAQ: AMGN - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) NASDAQ: IAM - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) NASDAQ: SPRB - [ImageneBio](https://aibio.space/companies/imagenebio/) NASDAQ: IMA - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) NASDAQ: SNDX ### Also on OTC - [Oncology Pharma](https://aibio.space/companies/oncology-pharma/) ONPH - [NIKA PHARMACEUTICALS, INC](https://aibio.space/companies/nika-pharmaceuticals/) NIKA - [ESCALON MEDICAL CORP](https://aibio.space/companies/escalon-medical/) ESMC - [INTERPACE BIOSCIENCES, INC.](https://aibio.space/companies/interpace-biosciences/) IDXG - [PaxMedica](https://aibio.space/companies/paxmedica/) PXMD - [Cell Source](https://aibio.space/companies/cell-source/) CLCS ## What Mosaic ImmunoEngineering does Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. It has historically advanced early-stage product candidates and is pursuing new product candidates and platforms to build a pipeline. Its corporate history includes a license option and then a license from Case Western Reserve University for the cowpea mosaic virus (CPMV) platform technology, to treat and prevent cancer and infectious diseases. That license was terminated on March 22, 2024. In April 2024 the company entered a binding term sheet with Oncotelic Therapeutics, Inc. to acquire rights to clinical stage necroptosis cancer therapies associated with vascular disruptive agents, along with non-exclusive access to Oncotelic's artificial intelligence technologies for identifying immunotherapy combinations. That term sheet expired on June 30, 2025, and the text says discussions are ongoing to bring in a technology portfolio. The company says its funding has primarily come from the issuance of convertible notes. | Product or program | What it is | Stage | |---|---|---| | CPMV platform | Cowpea mosaic virus platform for cancer and infectious diseases | license terminated March 22, 2024 | | Oncotelic necroptosis cancer therapies | Proposed rights to clinical stage vascular disruptive agent therapies | binding term sheet expired June 30, 2025 | Summarised from the company's [10-K filed Apr 15, 2026](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/mosaic_i10k-123125.htm). ## Mosaic ImmunoEngineering annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$63,981](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/) | [$183,867](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/) | | Net income (loss) | [-$687,846](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/) | [-$921,983](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/) | | Cash from operations | [-$111,397](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/) | [-$241,159](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/) | | Cash and equivalents | [$3,622](https://www.sec.gov/Archives/edgar/data/836564/000168316826006426/) | [$115,019](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $26. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Mosaic ImmunoEngineering What is the ticker symbol of Mosaic ImmunoEngineering? Mosaic ImmunoEngineering Inc. trades under the ticker CPMV on OTC. Where is Mosaic ImmunoEngineering listed? Mosaic ImmunoEngineering Inc. is listed on OTC. What is the SEC CIK of Mosaic ImmunoEngineering? The SEC Central Index Key (CIK) for Mosaic ImmunoEngineering Inc. is 836564. Its filings are on SEC EDGAR. How many shares does Mosaic ImmunoEngineering have outstanding? 7,242,137 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Mosaic ImmunoEngineering listed under? Our directory records Mosaic ImmunoEngineering Inc. under United States. What does Mosaic ImmunoEngineering do? Our directory classifies Mosaic ImmunoEngineering Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Mosaic ImmunoEngineering? The ISIN recorded for Mosaic ImmunoEngineering Inc. is US61945M1018. Does aibio.space cover Mosaic ImmunoEngineering? aibio.space lists Mosaic ImmunoEngineering Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Mosaic ImmunoEngineering incorporated? SEC records list its state or country of incorporation as DE. What does Mosaic ImmunoEngineering develop? Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. It has historically advanced early-stage product candidates and is pursuing new product candidates and platforms to build a pipeline. What is CPMV platform from Mosaic ImmunoEngineering? CPMV platform: Cowpea mosaic virus platform for cancer and infectious diseases Stage: license terminated March 22, 2024. What is Oncotelic necroptosis cancer therapies from Mosaic ImmunoEngineering? Oncotelic necroptosis cancer therapies: Proposed rights to clinical stage vascular disruptive agent therapies Stage: binding term sheet expired June 30, 2025. Is Mosaic ImmunoEngineering profitable? Mosaic ImmunoEngineering Inc. reported a net loss of $687,846 for the fiscal year ended Dec 31, 2025, and used $111,397 of cash in operations, per its annual report to the SEC. How much does Mosaic ImmunoEngineering spend on research and development? $63,981 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Mosaic ImmunoEngineering have? $26 in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Mosaic ImmunoEngineering Members talk about Mosaic ImmunoEngineering (CPMV). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Mosaic ImmunoEngineering, newest first. Each line links the filing it comes from. 1. 2026-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/836564/000168316826003965/mosaic_nt10q.htm) 2. 2026-03-31 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/836564/000168316826002497/mosaic_ext.htm) 3. 2025-11-12 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/836564/000168316825008256/mosaic_10qextension.htm) 4. 2025-08-12 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/836564/000168316825005982/mosaic_ext.htm) 5. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/836564/000168316825003643/mosaic_ext.htm) 6. 2025-03-28 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/836564/000168316825001988/mosaic_ext.htm) 7. 2024-11-13 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/836564/000168316824007963/mosaic_nt10q.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:CPMV on TradingView](https://www.tradingview.com/symbols/OTC-CPMV/). ## SEC filings and registration - **SEC name**: Mosaic ImmunoEngineering Inc. - **CIK**: 836564 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CPMV (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 9114 ADAMS AVE., HUNTINGTON BEACH, CA, 92646 - **Phone**: 657-208-0890 - **Shares outstanding**: 7,242,137 as of 2026-08-14 (10-Q filed 2026-08-14) - **Former names**: PATRIOT SCIENTIFIC CORP ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/836564/000168316826006426/mosaic_i10q-063026.htm) filed 2026-08-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/836564/000168316826004152/mosaic_i10q-033126.htm) filed 2026-05-20 - [10-K](https://www.sec.gov/Archives/edgar/data/836564/000168316826002977/mosaic_i10k-123125.htm) filed 2026-04-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/836564/000168316825008543/mosaic_i10q-093025.htm) filed 2025-11-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/836564/000168316825006318/mosaic_i10q-063025.htm) filed 2025-08-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/836564/000168316825003880/mosaic_i10q-033125.htm) filed 2025-05-20 - [10-K](https://www.sec.gov/Archives/edgar/data/836564/000168316825002584/mosaic_i10k-123124.htm) filed 2025-04-15 - [8-K](https://www.sec.gov/Archives/edgar/data/836564/000168316825000009/mosaic_8k.htm) filed 2025-01-02 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000836564), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Mosaic ImmunoEngineering Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker CPMV, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Mosaic ImmunoEngineering Inc. - **Ticker**: CPMV - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US61945M1018 - **Last quote in directory**: 2026-10-09 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-CPMV/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/mosaic-immunoengineering/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Mosaic ImmunoEngineering (CPMV) stock and investor profile", 2026-10-31, https://aibio.space/companies/mosaic-immunoengineering/